A Piroxicam Derivative Partly Effective in Chronic Paroxysmal Hemicrania and Hemicrania Continua

Authors

  • Dr. Ottar Sjaastad MD, PhD,

    1. From the Department of Neurology, Trondheim (Norway) University Hospitals and
    Search for more papers by this author
  • Dr. Fabio Antonaci MD

    Corresponding author
    1. the Headache Centre, “C. Mondino Foundation” University of Pavia, Italy.
      Dr. Fabio Antonaci, Headache Centre, “C. Mondino Foundation” University of Pavia, via Palestro 3, 27100 Pavia, Italy.
    Search for more papers by this author

Dr. Fabio Antonaci, Headache Centre, “C. Mondino Foundation” University of Pavia, via Palestro 3, 27100 Pavia, Italy.

Abstract

Piroxicam beta-cyclodextrin has recently been observed to be equal to, or even possibly to be superior to, indomethacin (mainly with regard to side effects) in a single case of hemicrania continua. Piroxicam beta-cyclodextrin, 20 to 40 mg per day, was, accordingly, tried in six patients with chronic paroxysmal hemicrania and six patients with hemicrania continua with a previously proven response to indomethacin. The study was conducted over a period of 3 weeks and in an open fashion. A placebo effect is considered to be negligible in these disorders. In such a comparison, piroxicam beta-cyclodextrin seemed inferior to indomethacin, in particular in chronic paroxysmal hemicrania.

Ancillary